New York, NY -- (ReleaseWire) -- 04/04/2025 -- As a preclinical contract research provider dedicated to offering comprehensive research services, Ace Therapeutics provides a complete one-stop service for developing custom animal models to support preclinical psychiatry research. The opportunity to apply such models towards revolutionizing research in mental health can allow for the discovery of novel therapies for these disorders.

"Psychiatry research faces a number of hurdles to the translation of?preclinical discoveries into effective treatments," said the senior chief scientist at Ace Therapeutics. "We pride?ourselves on being able to create customized animal models, enabling researchers to make more sense of the complexities surrounding mental health disorders and developing efficient therapeutic adjuncts."

Current challenges in preclinical psychiatry research
At this stage, preclinical research on mental diseases has many challenges and difficulties, such as animal models are limited, pathological mechanisms are complex, drug targets are unclear, and behavioral testing methods are?not advanced enough. To this end, preclinical studies on psychiatric disorders may have to create?more productive animal and in vitro models and enhance biomarker discovery and validation to accelerate the discovery of novel therapeutic strategies for psychiatric diseases.

Through approaches such as selective breeding, genetic engineering, brain injury, and environmental manipulation, Ace Therapeutics has developed a range of?animal models for psychiatric research. These models represent attempts to simulate, as?much as possible, the neurobiological or behavioral pathology of human diseases. Therefore, it can help researchers elucidate disease pathophysiology and also expedite therapeutic development?targeting novel molecular targets.

Some of the main features of?Ace Therapeutics' animal models include:
– Genetically-Engineered?Models: Models that can be genetically engineered to manifest specific traits related to different psychiatric conditions such as depression, anxiety, and autism, enabling targeted research.
- Robust Validation: Extensive?validation studies are performed with experienced psychiatric researchers to confirm that the models accurately represent human pathophysiology.

In this context, the launch of Ace Therapeutics' preclinical psychiatry models comes in response to increasing demand for better preclinical?research tools. Utilizing leading-edge genetic modification and behavioral evaluation techniques, Ace Therapeutics offers researchers the?ability to model a multitude of psychiatric disorders with unparalleled precision. The company is confident that these models can facilitate groundbreaking discoveries and accelerate the pathway from bench to bedside.

About Ace Therapeutics
With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative mental illness therapies. From basic research services to therapeutic development services, Ace Therapeutics offers tailored solutions to facilitate psychiatric drug development, enabling the transformation of promising concepts into promising therapeutic candidates.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

New York, NY -- (ReleaseWire) -- 05/30/2024 -- Ace Therapeutics, an integrated service provider for glaucoma research, is proud to announce the release of its proteomic analysis services for glaucoma research. These cutting-edge analysis services are expected to revolutionize the way researchers approach the study of glaucoma, a leading cause of irreversible blindness worldwide.

Glaucoma is a group of eye diseases characterized by damage to the optic nerve, usually due to high intraocular pressure (IOP). If not diagnosed and treated early, glaucoma can lead to loss of vision. There are several types of glaucoma, including open-angle, closed-angle, normal-tension, and congenital. Proteomics is the study of proteins and their functions within a biological system. Proteomics studies can help researchers uncover glaucoma-related changes in different tissues and biological fluids of the eye. By utilizing state-of-the-art technologies and techniques, Ace Therapeutics's proteomic analysis services will allow researchers to better understand the molecular mechanisms underlying glaucoma and develop innovative treatment strategies.

"Glaucoma is a complex disease with a significant impact on millions of people around the world. Our proteomic analysis services can provide researchers with invaluable insights into the biological pathways involved in glaucoma and pave the way for new therapeutic interventions." said the chief scientific officer at Ace Therapeutics.

Realizing the aqueous humor (AH) is a key site for studying the pathogenesis of glaucoma, Ace Therapeutics's team of experts can conduct quantitative glaucoma AH proteomic analysis to detect changes in protein expression, offering valuable information for biomarker discovery and enhancing the knowledge of the molecular mechanisms of glaucoma. Additionally, the company can also provide proteomic analysis of vitreous humor (VH) services to assist researchers in discussing and expanding their findings on glaucoma.

At Ace Therapeutics, its expert team will take care of the sample preparation of different ocular tissues and biological fluids associated with glaucoma, complex analytical experiments as well as data analysis using mass spectrometry, bioinformatics, and many other advanced technologies and facilities. These services are tailored to meet the specific needs of researchers working in both academic and industry settings.

About Ace Therapeutics
Ace Therapeutics Glaucoma is an innovative glaucoma disease research company that offers a wide range of services in basic research, drug development, and preclinical studies, delivering innovative and high-quality solutions to worldwide clients. Ace Therapeutics is committed to being a leader in the field of glaucoma research, providing unique drug development and preclinical research solutions to advance clients' project development.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm